Associations of Glycemic Control, Age, and Sex with Diabetic Foot Risk and Active Foot Ulceration among Patients with Diabetes in Saudi Arabia: A Cross-Sectional Study.
Fatimah Z Alenazi, Thamer Alslamah, Basmah Alharbi, Wafa I Alotaibi, Mirna Fawaz, Metab Algeffari, Yasir S Alsalamah, António Raposo
{"title":"Associations of Glycemic Control, Age, and Sex with Diabetic Foot Risk and Active Foot Ulceration among Patients with Diabetes in Saudi Arabia: A Cross-Sectional Study.","authors":"Fatimah Z Alenazi, Thamer Alslamah, Basmah Alharbi, Wafa I Alotaibi, Mirna Fawaz, Metab Algeffari, Yasir S Alsalamah, António Raposo","doi":"10.1007/s13300-026-01923-y","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Diabetic foot disease is one of the most severe complications of diabetes mellitus, contributing substantially to hospitalization, lower limb amputation, and premature mortality. This study evaluated the associations of glycemic control (glycated hemoglobin [HbA1c]), age, and sex with diabetic foot risk and ulceration among patients attending a tertiary diabetes center in Qassim, Saudi Arabia.</p><p><strong>Methods: </strong>This retrospective cross-sectional study included a census sample of 710 eligible electronic medical records of patients with a confirmed diagnosis of diabetes mellitus and a documented diabetic foot assessment between January 2022 and December 2024. No a priori sample size calculation was performed. The primary outcome was at-risk diabetic foot status (International Working Group on the Diabetic Foot category ≥ 1), and the secondary outcome was active foot ulceration. Multivariable logistic regression was used to identify factors independently associated with each outcome.</p><p><strong>Results: </strong>The mean age was 57.6 ± 14.0 years; 337 patients (47.5%) were male and 373 (52.5%) were female, and 93.2% had type 2 diabetes mellitus. At-risk diabetic foot status was present in 53.2% of patients, and active foot ulceration was present in 3.0%. Ulcer prevalence increased across HbA1c categories (1.9%, 2.6%, and 6.3%), and at-risk status increased with age (39.6-62.1%). Older age (odds ratio [OR] = 1.028; 95% confidence interval [CI] 1.016-1.039; P < 0.001) and male sex (OR = 1.403; 95% CI 1.036-1.901; P = 0.029) were independently associated with the at-risk status. HbA1c was not independently associated with at-risk status (P = 0.422) or ulceration (P = 0.077).</p><p><strong>Conclusions: </strong>Ulcer prevalence increased with poorer glycemic control; however, the adjusted HbA1c-ulceration association was not significant in the primary model. Key confounders were unavailable in the dataset, including diabetes duration, neuropathy and peripheral arterial disease severity, and renal function. Therefore, residual confounding cannot be excluded, and HbA1c's role in diabetic foot risk should not be discounted. These findings suggest that diabetic foot screening and preventive care should be tailored to specific age and sex groups, involving multiple healthcare disciplines.</p>","PeriodicalId":11192,"journal":{"name":"Diabetes Therapy","volume":" ","pages":""},"PeriodicalIF":4.2000,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13300-026-01923-y","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Diabetic foot disease is one of the most severe complications of diabetes mellitus, contributing substantially to hospitalization, lower limb amputation, and premature mortality. This study evaluated the associations of glycemic control (glycated hemoglobin [HbA1c]), age, and sex with diabetic foot risk and ulceration among patients attending a tertiary diabetes center in Qassim, Saudi Arabia.
Methods: This retrospective cross-sectional study included a census sample of 710 eligible electronic medical records of patients with a confirmed diagnosis of diabetes mellitus and a documented diabetic foot assessment between January 2022 and December 2024. No a priori sample size calculation was performed. The primary outcome was at-risk diabetic foot status (International Working Group on the Diabetic Foot category ≥ 1), and the secondary outcome was active foot ulceration. Multivariable logistic regression was used to identify factors independently associated with each outcome.
Results: The mean age was 57.6 ± 14.0 years; 337 patients (47.5%) were male and 373 (52.5%) were female, and 93.2% had type 2 diabetes mellitus. At-risk diabetic foot status was present in 53.2% of patients, and active foot ulceration was present in 3.0%. Ulcer prevalence increased across HbA1c categories (1.9%, 2.6%, and 6.3%), and at-risk status increased with age (39.6-62.1%). Older age (odds ratio [OR] = 1.028; 95% confidence interval [CI] 1.016-1.039; P < 0.001) and male sex (OR = 1.403; 95% CI 1.036-1.901; P = 0.029) were independently associated with the at-risk status. HbA1c was not independently associated with at-risk status (P = 0.422) or ulceration (P = 0.077).
Conclusions: Ulcer prevalence increased with poorer glycemic control; however, the adjusted HbA1c-ulceration association was not significant in the primary model. Key confounders were unavailable in the dataset, including diabetes duration, neuropathy and peripheral arterial disease severity, and renal function. Therefore, residual confounding cannot be excluded, and HbA1c's role in diabetic foot risk should not be discounted. These findings suggest that diabetic foot screening and preventive care should be tailored to specific age and sex groups, involving multiple healthcare disciplines.
期刊介绍:
Diabetes Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all areas of diabetes. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged.
The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Diabetes Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.